Cammett, Tobin J.
Garlo, Katherine
Millman, Ellen E.
Rice, Kara
Toste, Catherine M.
Faas, Susan J.
Funding for this research was provided by:
Alexion
Article History
Accepted: 2 October 2022
First Online: 4 November 2022
Change Date: 4 March 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40291-023-00643-4
Declarations
:
: This research was wholly funded by Alexion, AstraZeneca Rare Disease, Boston, MA, USA, and did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.
: As described in the original study publication.
: As described in the original study publication.
: As described in the original study publication.
: All authors are employees and stockholders of Alexion, AstraZeneca Rare Disease, Boston, MA, USA.
: All authors met ICMJE authorship criteria, contributed to the study conception and design, material preparation, data collection, critical review of the draft manuscript and approval of the final manuscript.
: Alexion will consider requests for disclosure of clinical study participant-level data provided that participant privacy is assured through methods like data de-identification, pseudonymization, or anonymization (as required by applicable law), and if such disclosure was included in the relevant study informed consent form or similar documentation. Qualified academic investigators may request participant-level, deidentified clinical data and supporting documents (statistical analysis plan and protocol) pertaining to Alexion-sponsored studies. Further details regarding data availability, and instructions for requesting information are available in the Alexion Clinical Trials Disclosure and Transparency Policy at ExternalRef removed.
: Not applicable.